Navigation Links
PharmAthene Reports Year-End 2012 Financial And Operational Results
Date:3/13/2013

ANNAPOLIS, Md., March 13, 2013 /PRNewswire/ --

Year-End 2012 Highlights

  • Received favorable final order and judgment from Delaware Chancery Court against SIGA Technologies
  • Accelerated funding for bioscavenger program under Department of Defense contract
  • Strengthened financial position and secured $7.5 million credit facility
  • Achieved 70% year-over-year reduction in operating cash usage
  • PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported its financial and operational results for the year ended December 31, 2012.

    "During the year, the Delaware Court of Chancery issued its final order and judgment awarding PharmAthene a significant economic interest in SIGA's smallpox antiviral therapeutic, Arestvyr™ (formerly known as ST-246®)," said Eric I. Richman, President and Chief Executive Officer. "This represented a major victory for our Company, which, if upheld by the Delaware Supreme Court, should enable us to accelerate our profitability and generate enhanced value for PharmAthene shareholders near-term. Oral arguments on the appeal were held in Delaware Supreme Court in January 2013 and we look forward to the Court's ruling."

    "We also made important technical progress in our next generation recombinant bioscavenger (rBChE) program and are poised to begin pharmacokinetic and non-clinical efficacy testing in the coming months. In recognition of this progress, last year the Department of Defense exercised its option under our current contract to accelerate funding for the rBChE program," said Mr. Richman. "Regarding our SparVax® anthrax vaccine program, we received notification from the Food and Drug Administration (FDA) that our proposed Phase II clinical study of SparVax® was being placed on clinical hold pending the provision of additional dat
    '/>"/>

    SOURCE PharmAthene, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
    2. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
    3. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
    4. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
    5. PharmAthene Reports First Quarter 2012 Financial Results
    6. PharmAthene Reports Third Quarter 2012 Financial Results
    7. PharmAthene To Present At The Noble Financial 9th Annual Equity Conference On Tuesday, January 22, 2013
    8. PharmAthene To Host Year-End 2012 Conference Call And Webcast On Wednesday, March 13, 2013
    9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/1/2014)... , Aug. 1, 2014 One of ... rise of personalized medicine, which is the practice of ... treatments to a patient,s individual biology. Personalized diagnostics—laboratory analyses ... major role in the lab,s future. This fall, ... feature the latest science in this exciting field and ...
    (Date:8/1/2014)... Research and Markets has announced the addition ... and Analysis Market 2014-2018" report to their offering. ... Single Nucleotide Polymorphism (SNP) genotyping is the screening and ... of various species. SNPs are commonly present in all ... analyze thousands of SNPs and has the potential for ...
    (Date:8/1/2014)... N.J., Aug. 1, 2014 Cambrex Corporation (NYSE: ... June 30, 2014. Highlights , ... million in the same period last year. , Second ... million in the same period last year (see table at ... sales guidance increased, excluding the impact of foreign currency, to ...
    (Date:7/31/2014)... Food and natural product manufacturers, ... food alternatives that offer variety, as well as, ... market has numerous players operating in the marketplace ... Technology (VFT). VFT is a science-driven functional ... all tested to produce stable, effective and repeatable ...
    Breaking Biology Technology:First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018 2Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2
    ... Advanced Chemical Transport, one of the leading ... with Gilead Sciences Inc., North America,s third largest Bio-Med ... - including hazardous Materials disposal, vacuum truck services, spill ... from its corporate headquarters in Sunnyvale, CA. , ...
    ... BC, July 2 /PRNewswire-FirstCall/ - avVaa World Health ... biotechnology company, manufacturer and distributor of nationally branded ... the engagement of Koeppel Direct to manage their ... of avVaa World Health Care is excited to ...
    ... - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ... completed in the Phase II component of a Phase ... patients with advanced cancers. The principal investigators for the ... Cancer Research, London, England, and Dr. Geoff Hall of ...
    Cached Biology Technology:avVaa World Health Care Products, Inc. Announces Engagement of Koeppel Direct for their DRTV-Direct Response Television Media Buying Campaign 2Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial 2
    (Date:7/31/2014)... the roughly 156,000 gas stations across the United ... of underground gas storage tankscorrosion that could result ... source of drinking water. In recent years, field ... corroding gas storage tank components such as sump ... of gasoline-ethanol blends and the presence of bacteria, ...
    (Date:7/31/2014)... An experimental vaccine protected 100 percent of animal models ... difficile , which causes an intestinal disease that kills ... of print in Infection and Immunity . ... and non-human primates against the purified toxins produced by ... orogastric spore infection, a laboratory model that mimics the ...
    (Date:7/31/2014)... step has been made to help better identify and treat ... abnormal narrowing and enlarging of medium sized arteries in the ... other organs causing damage. In a new report appearing in ... , scientists provide evidence that that FMD may not be ... show a connection to abnormalities of bones and joints, as ...
    Breaking Biology News(10 mins):NIST corrosion lab tests suggest need for underground gas tank retrofits 2C. difficile vaccine proves safe, 100 percent effective in animal models 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2
    ... a trigger that induces B cells to produce effective and ... a molecule that binds toll-like receptors (TLR) doubles the early ... more effective, IgG form. , The findings, published online and ... of Experimental Medicine , support the emerging concept of ,bridge ...
    ... July 6 Aware, Inc. (Nasdaq: ... software, today announced that it has supplied its Biometric ... police agency analogous to the U.S. FBI. BioSP is ... product being used by the police agency for several ...
    ... a new means of determining the sex of skeletal human ... the wake of disasters, the studying of ancient remains and ... able to determine the sex of skeletal remains by visually ... coxa. "This technique is accurate, but is not without its ...
    Cached Biology News:Researchers discover trigger to early, effective antibody response 2Researchers discover trigger to early, effective antibody response 3Aware's Biometric Services Platform (BioSP) Deployed By a Large European Police Agency 2Aware's Biometric Services Platform (BioSP) Deployed By a Large European Police Agency 3Aware's Biometric Services Platform (BioSP) Deployed By a Large European Police Agency 4Hips don't lie: Researchers find more accurate technique to determine sex of skeletal remains 2
    Healthy animals 10-32 weeks of age, mixed gender and breed; collected on wet ice following USDA guidelines, using Alsevers solution at 1:2 dilution...
    ... for Sequencing allow 5-minute cloning and subsequent sequencing ... vectors with primer sites located as close as ... site. This minimizes the amount of vector DNA ... sequence of your insert.vectors are available. The pCR4-TOPO ...
    Carp Vitellogenin ELISA System, 96 wells. ELISARange: 5.0-225 ng/ml.Sensitivity: 5.0 ng/ml.Sample volume: 100 ul.Suitable for use with Carp plasma samples.3-h protocol.Store at 2-8 C. Category: Drug ...
    Quartz-Halogen, 100 W, High Intensity...
    Biology Products: